10 Pharma Stocks With 100% Buy Ratings
The company is expected to report a loss of 40 cents per share during 2010 fourth quarter, compared to loss of 49 cents per share and 46 cents per share in the year-ago and quarter-ago periods, respectively, as per Analysts polled by Bloomberg. For the full year, loss per share is forecast at $1.55 cents for 2010 in comparison to loss of $1.68 per share for 2009. Analysts estimate the company to turn profitable in 2011 on earnings of 2 cents per share.
The return-on-equity during the past 12 months has been 25.2%. In comparison, Pfizer, Biogen Idec (BIIB), Endo Pharmaceuticals (ENDP) and OXiGENE (OXGN) have ROEs of 11.7%, 17.2%, 19.7% and -279.7%, respectively.
All the five analysts covering the stock recommend buying and estimate the stock to gain around 143% over the next 12 months with a consensus target price of $12.0.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
